| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 49 | 2025 | 1422 | 3.760 |
Why?
|
| Heart-Assist Devices | 42 | 2025 | 898 | 3.460 |
Why?
|
| Cardiomyopathies | 14 | 2025 | 285 | 3.020 |
Why?
|
| Amyloidosis | 13 | 2025 | 139 | 2.380 |
Why?
|
| Amyloid Neuropathies, Familial | 9 | 2025 | 38 | 2.020 |
Why?
|
| Hemodynamics | 18 | 2022 | 775 | 1.430 |
Why?
|
| Ventricular Function, Left | 15 | 2025 | 662 | 1.120 |
Why?
|
| Prealbumin | 9 | 2025 | 42 | 1.020 |
Why?
|
| Heart Transplantation | 8 | 2024 | 811 | 0.920 |
Why?
|
| Pulmonary Wedge Pressure | 10 | 2021 | 123 | 0.860 |
Why?
|
| Echocardiography | 10 | 2025 | 1004 | 0.740 |
Why?
|
| Cardiac Catheterization | 10 | 2019 | 330 | 0.710 |
Why?
|
| Heart Ventricles | 10 | 2024 | 810 | 0.690 |
Why?
|
| Diflunisal | 1 | 2020 | 1 | 0.660 |
Why?
|
| Heart Valve Diseases | 3 | 2024 | 121 | 0.660 |
Why?
|
| Immunoglobulin Light-chain Amyloidosis | 4 | 2024 | 25 | 0.640 |
Why?
|
| Intra-Aortic Balloon Pumping | 5 | 2024 | 92 | 0.610 |
Why?
|
| Middle Aged | 55 | 2025 | 28206 | 0.550 |
Why?
|
| Male | 62 | 2025 | 45685 | 0.520 |
Why?
|
| Retrospective Studies | 31 | 2025 | 10273 | 0.490 |
Why?
|
| Aged | 43 | 2025 | 20848 | 0.490 |
Why?
|
| Humans | 80 | 2025 | 95799 | 0.470 |
Why?
|
| Female | 59 | 2025 | 49869 | 0.470 |
Why?
|
| Prospective Studies | 16 | 2025 | 4664 | 0.400 |
Why?
|
| Prosthesis Implantation | 3 | 2019 | 131 | 0.390 |
Why?
|
| Aortic Valve Insufficiency | 3 | 2021 | 143 | 0.390 |
Why?
|
| Shock, Cardiogenic | 2 | 2021 | 172 | 0.310 |
Why?
|
| Coronary Artery Bypass | 3 | 2020 | 252 | 0.310 |
Why?
|
| Ventricular Dysfunction, Left | 3 | 2024 | 340 | 0.300 |
Why?
|
| Azithromycin | 1 | 2009 | 17 | 0.300 |
Why?
|
| Drug Hypersensitivity | 1 | 2009 | 40 | 0.290 |
Why?
|
| Postoperative Complications | 6 | 2025 | 2592 | 0.280 |
Why?
|
| Myocarditis | 1 | 2009 | 58 | 0.280 |
Why?
|
| Mitral Valve Insufficiency | 2 | 2024 | 209 | 0.280 |
Why?
|
| Pacemaker, Artificial | 2 | 2020 | 105 | 0.270 |
Why?
|
| Echocardiography, Doppler | 3 | 2018 | 193 | 0.270 |
Why?
|
| Treatment Outcome | 17 | 2024 | 9167 | 0.270 |
Why?
|
| Thromboembolism | 2 | 2018 | 128 | 0.270 |
Why?
|
| Device Removal | 2 | 2019 | 166 | 0.260 |
Why?
|
| Thrombosis | 2 | 2020 | 326 | 0.260 |
Why?
|
| Benzoxazoles | 2 | 2024 | 4 | 0.250 |
Why?
|
| Hemorrhage | 2 | 2018 | 294 | 0.250 |
Why?
|
| Predictive Value of Tests | 8 | 2025 | 1805 | 0.240 |
Why?
|
| Prognosis | 9 | 2025 | 3990 | 0.240 |
Why?
|
| Cannula | 4 | 2019 | 57 | 0.240 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2018 | 246 | 0.230 |
Why?
|
| Stroke Volume | 4 | 2025 | 531 | 0.230 |
Why?
|
| Heart Function Tests | 2 | 2018 | 33 | 0.220 |
Why?
|
| Ventricular Function, Right | 3 | 2025 | 160 | 0.210 |
Why?
|
| Cardiotonic Agents | 2 | 2019 | 95 | 0.210 |
Why?
|
| Cardiac Output | 3 | 2022 | 159 | 0.210 |
Why?
|
| Aged, 80 and over | 6 | 2025 | 7215 | 0.210 |
Why?
|
| Cardiac Valve Annuloplasty | 1 | 2023 | 15 | 0.200 |
Why?
|
| Atrioventricular Block | 1 | 2023 | 27 | 0.200 |
Why?
|
| Graft Rejection | 2 | 2020 | 1126 | 0.200 |
Why?
|
| Anti-Bacterial Agents | 1 | 2009 | 847 | 0.200 |
Why?
|
| Central Venous Pressure | 2 | 2020 | 28 | 0.190 |
Why?
|
| Anticoagulants | 4 | 2019 | 463 | 0.190 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2025 | 167 | 0.190 |
Why?
|
| Health Status Disparities | 1 | 2025 | 221 | 0.190 |
Why?
|
| Observational Studies as Topic | 1 | 2022 | 56 | 0.180 |
Why?
|
| Mononeuropathies | 1 | 2022 | 8 | 0.180 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2023 | 129 | 0.180 |
Why?
|
| Echocardiography, Three-Dimensional | 2 | 2017 | 528 | 0.180 |
Why?
|
| RNA, Small Interfering | 1 | 2023 | 562 | 0.180 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2023 | 197 | 0.170 |
Why?
|
| Aortic Rupture | 1 | 2022 | 58 | 0.170 |
Why?
|
| Time Factors | 8 | 2025 | 5561 | 0.170 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2022 | 102 | 0.170 |
Why?
|
| Aftercare | 1 | 2021 | 90 | 0.170 |
Why?
|
| Arterial Pressure | 2 | 2018 | 42 | 0.170 |
Why?
|
| Lactic Acid | 1 | 2021 | 108 | 0.170 |
Why?
|
| Immunosuppressive Agents | 2 | 2020 | 995 | 0.160 |
Why?
|
| Rare Diseases | 1 | 2020 | 71 | 0.160 |
Why?
|
| Follow-Up Studies | 7 | 2025 | 3904 | 0.160 |
Why?
|
| Antidiuretic Hormone Receptor Antagonists | 1 | 2020 | 28 | 0.160 |
Why?
|
| Mathematical Concepts | 1 | 2020 | 19 | 0.160 |
Why?
|
| Heart | 2 | 2023 | 590 | 0.150 |
Why?
|
| Survival Rate | 5 | 2025 | 1971 | 0.150 |
Why?
|
| Healthcare Disparities | 1 | 2025 | 491 | 0.150 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2020 | 82 | 0.150 |
Why?
|
| Tachycardia, Ventricular | 1 | 2020 | 132 | 0.150 |
Why?
|
| Electric Impedance | 1 | 2020 | 112 | 0.150 |
Why?
|
| Pulmonary Artery | 2 | 2021 | 340 | 0.150 |
Why?
|
| Sternotomy | 1 | 2019 | 24 | 0.150 |
Why?
|
| Thyroid Diseases | 1 | 2019 | 106 | 0.150 |
Why?
|
| Remote Sensing Technology | 1 | 2018 | 9 | 0.150 |
Why?
|
| Assisted Circulation | 1 | 2018 | 16 | 0.150 |
Why?
|
| Adult | 17 | 2024 | 28578 | 0.150 |
Why?
|
| Counterpulsation | 1 | 2018 | 21 | 0.140 |
Why?
|
| Transplant Recipients | 1 | 2020 | 157 | 0.140 |
Why?
|
| Testosterone | 1 | 2019 | 276 | 0.140 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2018 | 56 | 0.140 |
Why?
|
| Enoxaparin | 1 | 2018 | 25 | 0.140 |
Why?
|
| Catheter Ablation | 1 | 2020 | 266 | 0.140 |
Why?
|
| Octreotide | 1 | 2018 | 29 | 0.140 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2018 | 158 | 0.140 |
Why?
|
| Cardiac Resynchronization Therapy | 1 | 2019 | 83 | 0.140 |
Why?
|
| Patient Readmission | 2 | 2019 | 413 | 0.130 |
Why?
|
| Cohort Studies | 6 | 2022 | 3106 | 0.130 |
Why?
|
| Risk Factors | 7 | 2025 | 5961 | 0.130 |
Why?
|
| Thermodilution | 1 | 2017 | 20 | 0.130 |
Why?
|
| Endothelium, Vascular | 2 | 2010 | 437 | 0.130 |
Why?
|
| Risk Assessment | 3 | 2025 | 2480 | 0.130 |
Why?
|
| Ambulatory Care | 1 | 2018 | 198 | 0.130 |
Why?
|
| Insulin Resistance | 1 | 2019 | 380 | 0.130 |
Why?
|
| Magnetic Resonance Imaging, Cine | 3 | 2025 | 172 | 0.130 |
Why?
|
| Secondary Prevention | 1 | 2018 | 179 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 284 | 0.130 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 296 | 0.130 |
Why?
|
| Heart Diseases | 1 | 2018 | 314 | 0.120 |
Why?
|
| Defibrillators, Implantable | 1 | 2018 | 156 | 0.120 |
Why?
|
| Kidney Failure, Chronic | 1 | 2020 | 432 | 0.120 |
Why?
|
| Serotonin | 1 | 2016 | 219 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 346 | 0.110 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 1739 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 334 | 0.110 |
Why?
|
| Liver Transplantation | 1 | 2022 | 1201 | 0.110 |
Why?
|
| Incidence | 4 | 2021 | 1714 | 0.110 |
Why?
|
| Ventricular Remodeling | 2 | 2025 | 114 | 0.100 |
Why?
|
| Hospitalization | 1 | 2019 | 943 | 0.100 |
Why?
|
| Immunoglobulin Light Chains | 2 | 2024 | 91 | 0.100 |
Why?
|
| Kidney Transplantation | 1 | 2020 | 882 | 0.100 |
Why?
|
| Diabetes Mellitus | 1 | 2019 | 771 | 0.090 |
Why?
|
| Carney Complex | 1 | 2012 | 3 | 0.090 |
Why?
|
| Hospital Mortality | 2 | 2019 | 483 | 0.090 |
Why?
|
| Prosthesis Design | 3 | 2019 | 310 | 0.090 |
Why?
|
| Physicians | 1 | 2019 | 706 | 0.090 |
Why?
|
| Electrocardiography | 2 | 2015 | 522 | 0.090 |
Why?
|
| Lung | 1 | 2018 | 1380 | 0.090 |
Why?
|
| Proportional Hazards Models | 3 | 2019 | 900 | 0.090 |
Why?
|
| Coronary Artery Disease | 1 | 2016 | 394 | 0.090 |
Why?
|
| Biomarkers | 3 | 2025 | 1931 | 0.080 |
Why?
|
| Case-Control Studies | 2 | 2025 | 1957 | 0.080 |
Why?
|
| Recurrence | 3 | 2018 | 1211 | 0.080 |
Why?
|
| Decision Trees | 1 | 2010 | 63 | 0.080 |
Why?
|
| Causality | 1 | 2010 | 84 | 0.080 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2010 | 67 | 0.080 |
Why?
|
| Diuretics | 1 | 2010 | 77 | 0.080 |
Why?
|
| Vasoconstrictor Agents | 1 | 2010 | 68 | 0.080 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2010 | 98 | 0.080 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2009 | 62 | 0.070 |
Why?
|
| Prevalence | 2 | 2024 | 1349 | 0.070 |
Why?
|
| Azathioprine | 1 | 2009 | 125 | 0.070 |
Why?
|
| Prednisone | 1 | 2009 | 252 | 0.070 |
Why?
|
| Fibrinolytic Agents | 1 | 2010 | 240 | 0.070 |
Why?
|
| Equipment Failure | 2 | 2018 | 128 | 0.060 |
Why?
|
| Aortic Valve | 2 | 2021 | 273 | 0.060 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 787 | 0.060 |
Why?
|
| Glucocorticoids | 1 | 2009 | 369 | 0.060 |
Why?
|
| Recovery of Function | 2 | 2019 | 348 | 0.060 |
Why?
|
| Comorbidity | 2 | 2020 | 1011 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 1613 | 0.060 |
Why?
|
| Disease Progression | 2 | 2021 | 1559 | 0.060 |
Why?
|
| Caribbean Region | 1 | 2025 | 27 | 0.060 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2024 | 60 | 0.050 |
Why?
|
| Amyloidosis, Familial | 1 | 2023 | 2 | 0.050 |
Why?
|
| Amyloid | 1 | 2024 | 105 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2024 | 182 | 0.050 |
Why?
|
| Technetium Tc 99m Pyrophosphate | 1 | 2022 | 9 | 0.050 |
Why?
|
| Technetium | 1 | 2022 | 27 | 0.050 |
Why?
|
| Diphosphates | 1 | 2022 | 18 | 0.050 |
Why?
|
| Gadolinium | 1 | 2023 | 106 | 0.050 |
Why?
|
| Thorax | 1 | 2023 | 79 | 0.050 |
Why?
|
| Tricuspid Valve | 1 | 2023 | 112 | 0.050 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2023 | 325 | 0.050 |
Why?
|
| ROC Curve | 1 | 2024 | 797 | 0.040 |
Why?
|
| Waiting Lists | 1 | 2023 | 212 | 0.040 |
Why?
|
| Propensity Score | 1 | 2022 | 180 | 0.040 |
Why?
|
| Algorithms | 1 | 2010 | 2015 | 0.040 |
Why?
|
| Myocardium | 1 | 2024 | 592 | 0.040 |
Why?
|
| Catheterization, Swan-Ganz | 1 | 2021 | 24 | 0.040 |
Why?
|
| Axillary Artery | 1 | 2020 | 12 | 0.040 |
Why?
|
| Monitoring, Physiologic | 1 | 2021 | 273 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2018 | 2039 | 0.040 |
Why?
|
| Heart Atria | 1 | 2022 | 290 | 0.040 |
Why?
|
| Aorta | 1 | 2021 | 294 | 0.040 |
Why?
|
| Hyponatremia | 1 | 2020 | 30 | 0.040 |
Why?
|
| Euthyroid Sick Syndromes | 1 | 2019 | 11 | 0.040 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2020 | 62 | 0.040 |
Why?
|
| Tissue Donors | 1 | 2023 | 542 | 0.040 |
Why?
|
| Endocrine System Diseases | 1 | 2019 | 25 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 2020 | 303 | 0.040 |
Why?
|
| Consensus | 1 | 2021 | 370 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2023 | 1791 | 0.040 |
Why?
|
| Hyperthyroidism | 1 | 2019 | 76 | 0.040 |
Why?
|
| Muscle, Skeletal | 1 | 2022 | 483 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2020 | 147 | 0.040 |
Why?
|
| Metabolic Diseases | 1 | 2019 | 57 | 0.040 |
Why?
|
| Heparin | 1 | 2019 | 186 | 0.040 |
Why?
|
| United States | 2 | 2025 | 7764 | 0.040 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2022 | 217 | 0.040 |
Why?
|
| Systole | 1 | 2019 | 116 | 0.040 |
Why?
|
| Liver | 1 | 2023 | 1231 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2021 | 361 | 0.040 |
Why?
|
| Operative Time | 1 | 2019 | 167 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 2882 | 0.030 |
Why?
|
| Thyrotropin | 1 | 2019 | 311 | 0.030 |
Why?
|
| Coronary Circulation | 1 | 2018 | 133 | 0.030 |
Why?
|
| Contrast Media | 1 | 2023 | 1096 | 0.030 |
Why?
|
| Injections, Intramuscular | 1 | 2018 | 66 | 0.030 |
Why?
|
| International Normalized Ratio | 1 | 2018 | 38 | 0.030 |
Why?
|
| Muscle Contraction | 1 | 2019 | 294 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2018 | 161 | 0.030 |
Why?
|
| Hospitals, University | 1 | 2018 | 199 | 0.030 |
Why?
|
| Delayed-Action Preparations | 1 | 2018 | 117 | 0.030 |
Why?
|
| Neutropenia | 1 | 2018 | 211 | 0.030 |
Why?
|
| Thyroxine | 1 | 2019 | 388 | 0.030 |
Why?
|
| Hypothyroidism | 1 | 2019 | 276 | 0.030 |
Why?
|
| Risk | 1 | 2018 | 665 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 362 | 0.030 |
Why?
|
| Ultrasonography | 2 | 2010 | 747 | 0.030 |
Why?
|
| Patient Selection | 1 | 2020 | 708 | 0.030 |
Why?
|
| Equipment Safety | 1 | 2016 | 32 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2018 | 816 | 0.030 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2018 | 180 | 0.030 |
Why?
|
| Illinois | 1 | 2018 | 530 | 0.030 |
Why?
|
| Reoperation | 1 | 2019 | 707 | 0.030 |
Why?
|
| Gastrointestinal Agents | 1 | 2018 | 183 | 0.030 |
Why?
|
| Prosthesis Failure | 1 | 2016 | 125 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2018 | 1540 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 883 | 0.030 |
Why?
|
| Cause of Death | 1 | 2016 | 278 | 0.030 |
Why?
|
| Equipment Design | 1 | 2016 | 427 | 0.030 |
Why?
|
| Reference Values | 1 | 2016 | 674 | 0.030 |
Why?
|
| Chicago | 1 | 2019 | 1505 | 0.030 |
Why?
|
| Exercise Test | 1 | 2015 | 178 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 1008 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 1194 | 0.030 |
Why?
|
| Observer Variation | 1 | 2016 | 626 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 880 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 1965 | 0.030 |
Why?
|
| Sex Factors | 1 | 2016 | 1127 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2017 | 700 | 0.020 |
Why?
|
| Age Factors | 1 | 2016 | 1957 | 0.020 |
Why?
|
| Stroke | 1 | 2020 | 1087 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 2859 | 0.020 |
Why?
|
| Mutation | 1 | 2022 | 4374 | 0.020 |
Why?
|
| Brachial Artery | 1 | 2010 | 36 | 0.020 |
Why?
|
| Exercise Tolerance | 1 | 2010 | 66 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2009 | 236 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2009 | 983 | 0.010 |
Why?
|
| Adolescent | 1 | 2012 | 9873 | 0.010 |
Why?
|